Zacks Research Has Negative View of MetaVia FY2026 Earnings

MetaVia Inc. (NASDAQ:MTVA) – Analysts at Zacks Research reduced their FY2026 earnings per share (EPS) estimates for shares of MetaVia in a research report issued to clients and investors on Thursday, May 21st. Zacks Research analyst D. Bautz now anticipates that the company will earn ($1.87) per share for the year, down from their prior forecast of ($1.86). The consensus estimate for MetaVia’s current full-year earnings is ($2.78) per share.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Friday, April 24th. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of MetaVia in a report on Monday, May 18th. Finally, Wall Street Zen raised MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $20.00.

MetaVia Stock Down 22.9%

Shares of MetaVia stock opened at $2.97 on Wednesday. MetaVia has a 12-month low of $0.97 and a 12-month high of $19.03. The stock has a market cap of $15.33 million, a P/E ratio of -0.57 and a beta of 0.59. The business’s 50 day moving average is $1.56 and its 200-day moving average is $4.11.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03).

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC increased its holdings in shares of MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the quarter. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 as of its most recent SEC filing. 1.37% of the stock is currently owned by institutional investors and hedge funds.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.